Study of new treatment for youth with acute promyelocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 18 years old
- Have APL confirmed by a special gene fusion test (PML/RARα)
- Have parent/guardian consent for the study (or legal permission to join)
- Have healthy enough liver function for study safety
- Have kidneys working well enough for study safety
- No serious heart rhythm or heart weakness problems on tests (EKG and heart function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests whether an oral version of arsenic trioxide works as well as the IV version for people with a certain type of leukemia called APL. It aims to confirm that taking the drug by mouth has similar safety and effectiveness.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
Hear when a new Acute Promyelocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.